VA expands health care to PFAS-exposed veterans without proof
H.R. 3639 — VET PFAS Act · Filed by Michael Lawler (R-NY) · 30 cosponsors · Introduced May 29, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands VA health care to veterans and their family members who were exposed to PFAS (per- and polyfluoroalkyl substances, including the chemical PFOA) at military installations, and creates a legal presumption that certain diseases—including high cholesterol, ulcerative colitis, thyroid disease, testicular cancer, kidney cancer, and pregnancy-induced hypertension—are service-connected for PFAS-exposed veterans, eliminating the need to prove causation. The bill also extends presumptive coverage to family members who lived at contaminated installations or were in utero there.
Why we flagged it
The bill's core function is to extend VA hospital care and presumptive disability benefits to a specific population (PFAS-exposed veterans and families) without requiring proof of causation. This is a straightforward entitlement expansion, not a tax provision, deregulation, or appropriations rider.
What the text implies
- The bill ties presumptive coverage for non-PFOA PFAS substances to a 2018 NDAA study (Sec. 316, PL 115–91) that may not yet be complete or may not have reached Congress; the operative trigger and scope of family-member coverage thus depend on an external study's findings and timing, creating potential delays or scope uncertainty.
- Family members' eligibility is contingent on exhausting all third-party claims and remedies (including health-plan contracts) before VA coverage applies, making the VA a payer of last resort; this may create friction with private insurers and delay care while claims are pursued.
The full analysis lists 4 implications of this text.
Who stands to gain
VA (increased appropriations for hospital care and medical services); pharmaceutical companies (increased demand for treatments for presumed PFAS-related conditions); health care providers (increased VA reimbursements for care to veterans and family members)